This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2011 May 12;364(19):1788-90.

doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13.

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

B Nhi Beasley¹, Ellis F Unger, Robert Temple

Affiliations

Affiliation

¹ Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21488759
DOI: 10.1056/NEJMp1103050

Free article

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

B Nhi Beasley et al. N Engl J Med. 2011.

Free article

. 2011 May 12;364(19):1788-90.

doi: 10.1056/NEJMp1103050. Epub 2011 Apr 13.

Authors

B Nhi Beasley¹, Ellis F Unger, Robert Temple

Affiliation

¹ Division of Cardiovascular and Renal Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

PMID: 21488759
DOI: 10.1056/NEJMp1103050

No abstract available

PubMed Disclaimer

Similar articles

[Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
Panchenko EP. Panchenko EP. Kardiologiia. 2011;51(11):83-90. Kardiologiia. 2011. PMID: 22117775 Review. Russian. No abstract available.
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
Kowey PR, Naccarelli GV. Kowey PR, et al. Am J Med. 2012 Aug;125(8):732. doi: 10.1016/j.amjmed.2011.10.035. Epub 2012 May 18. Am J Med. 2012. PMID: 22608987 No abstract available.
Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.
Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S. Eikelboom JW, et al. J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042. Epub 2013 Jun 13. J Am Coll Cardiol. 2013. PMID: 23770182 Clinical Trial.
Place of dabigatran in contemporary pharmacotherapy.
Gums JG. Gums JG. Pharmacotherapy. 2011 Apr;31(4):335-7. doi: 10.1592/phco.31.4.335. Pharmacotherapy. 2011. PMID: 21449622 No abstract available.
Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
Berman JP, Halperin JL. Berman JP, et al. Hosp Pract (1995). 2013 Feb;41(1):37-48. doi: 10.3810/hp.2013.02.1006. Hosp Pract (1995). 2013. PMID: 23466966 Review.

See all similar articles

Cited by

The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective.
Stacy ZA, Richter SK. Stacy ZA, et al. Hosp Pharm. 2016 Jan;51(1):26-34. doi: 10.1310/hpj5101-26. Epub 2016 Jan 1. Hosp Pharm. 2016. PMID: 38745713 Free PMC article.
Quantitative Benefit-Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial.
Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs RM, Berkowitz SD, Haskell L, Barnathan ES, Bonaca MP. Yuan Z, et al. J Am Heart Assoc. 2024 Apr 16;13(8):e032782. doi: 10.1161/JAHA.123.032782. Epub 2024 Apr 2. J Am Heart Assoc. 2024. PMID: 38563380 Free PMC article. Clinical Trial.
Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National Prospective Registry: PAFF.
Guenoun M, Cohen S, Villaceque M, Sharareh A, Schwartz J, Hoffman O, Dib JC, Ouazana L, Assouline S, Parrens E, Garban T, Pradeau V, Guedj-Meynier D, Lequeux B, Cohen C, Durand P, Dievart F, Dhanjal TS, Sabouret P, Lellouche N. Guenoun M, et al. Europace. 2023 Oct 5;25(10):euad302. doi: 10.1093/europace/euad302. Europace. 2023. PMID: 37801642 Free PMC article.
Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis.
Joosten LPT, van Maanen R, van den Dries CJ, Rutten FH, Hoes AW, Granger CB, Hemels MEW, Geersing GJ, van Doorn S. Joosten LPT, et al. Open Heart. 2023 May;10(1):e002197. doi: 10.1136/openhrt-2022-002197. Open Heart. 2023. PMID: 37169490 Free PMC article.
Benefit-Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness.
Raskob GE, Ageno W, Albers G, Elliott CG, Halperin J, Maynard G, Steg PG, Weitz JI, Albanese J, Yuan Z, Levitan B, Lu W, Suh EY, Spiro T, Lipardi C, Barnathan ES, Spyropoulos AC. Raskob GE, et al. J Am Heart Assoc. 2022 Oct 18;11(20):e026229. doi: 10.1161/JAHA.122.026229. Epub 2022 Oct 7. J Am Heart Assoc. 2022. PMID: 36205248 Free PMC article. Clinical Trial.

See all "Cited by" articles

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information